Evidence map›Paper›PMID 38931178›Full record

ReviewNutrients2024

Exploring Functional Products and Early-Life Dynamics of Gut Microbiota.

Ana B Martínez-Martínez, Belen M Lamban-Per, Maria Lezaun, Antonio Rezusta, Jose M Arbones-Mainar

Abstract readReview
In one paragraph

Review in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ana B Martínez-MartínezFacultad de Ciencias de la Salud, Universidad de Zaragoza, 50009 Zaragoza, Spain.ORCID 0000-0002-1557-7545
Belen M Lamban-PerDepartment of Clinical Microbiology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0009-0001-3194-2661
Maria LezaunDepartment of Clinical Microbiology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Antonio RezustaInstituto de Investigación Sanitaria Aragón, 50009 Zaragoza, Spain.
Jose M Arbones-MainarDepartment of Clinical Microbiology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0000-0002-8982-3737

Funding

Gobierno de Aragón B03_23RIbercaja 216198 (JIUZ2022-SAL-03)Instituto de Salud Carlos III PI22/01366
6 · The paper itself

Abstract

Research on the microbiome has progressed from identifying specific microbial communities to exploring how these organisms produce and modify metabolites that impact a wide range of health conditions, including gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases. This review provides an overview of the bacteria commonly found in the intestinal tract, focusing on their main functional outputs. We explore biomarkers that not only indicate a well-balanced microbiota but also potential dysbiosis, which could foreshadow susceptibility to future health conditions. Additionally, it discusses the establishment of the microbiota during the early years of life, examining factors such as gestational age at birth, type of delivery, antibiotic intake, and genetic and environmental influences. Through a comprehensive analysis of current research, this article aims to enhance our understanding of the microbiota's foundational development and its long-term implications for health and disease management.

Indexed as

DysbiosisGastrointestinal MicrobiomeAnti-Bacterial AgentsBacteriaBiomarkersHumansInfantInfant, NewbornAnti-Bacterial AgentsBiomarkersdysbiosis biomarkersearly-life microbiotagut functional products

Identifiers

PMID38931178
PMCPMC11206896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.